Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Pipeline Review, H1 2018

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Pipeline Review, H1 2018


  • Products Id :- GMDHC1342TDB
  • |
  • Pages: 81
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Pipeline Review, H1 2018

Summary

According to the recently published report 'Growth Hormone Secretagogue Receptor Type 1-Pipeline Review, H1 2018'; Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 20 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland.

The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity.

The report 'Growth Hormone Secretagogue Receptor Type 1-Pipeline Review, H1 2018' outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 1, 9 and 3 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Toxicology, Metabolic Disorders, Central Nervous System, Cardiovascular, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Hormonal Disorders and Infectious Disease which include indications Cancer Anorexia-Cachexia Syndrome, Obesity, Prader-Willi Syndrome (PWS), Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Ischemic Stroke, Alcohol Addiction, Chemotherapy Effects, Chemotherapy Induced Peripheral Neuropathy, Chronic Kidney Disease (Chronic Renal Failure), Diabetes, Diabetic Gastroparesis, Fatigue, Growth Hormone Deficiency, Ischemia, Opioid-Induced Bowel Dysfunction (OBD or OIBD), Sepsis and Traumatic Brain Injury.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)

The report reviews Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects

The report assesses Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Overview

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Companies Involved in Therapeutics Development

Aeterna Zentaris Inc

Allergan Plc

AstraZeneca Plc

Daiichi Sankyo Co Ltd

Millendo Therapeutics Inc

Oxeia Biopharmaceuticals Inc

Pfizer Inc

RaQualia Pharma Inc

Zeria Pharmaceutical Co Ltd

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Drug Profiles

anamorelin hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZ-12861903-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZP-531-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXT-400-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXT-405-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-03-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-04-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibutamoren mesylate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

macimorelin acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OXE-103-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-05190457-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relamorelin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00433412-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Ghrelin Receptor for Obesity-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Ghrelin Receptor for Obesity-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ulimorelin hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Z-505-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Dormant Products

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Discontinued Products

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Product Development Milestones

Featured News & Press Releases

Jan 23, 2018: Lyric Pharmaceuticals Presents Data at ASPEN Conference on the Incidence of Enteral Feeding Intolerance in the ICU

Jan 17, 2018: Lyric Pharma Granted FDA Fast Track Designation for Lead Product Ulimorelin for Enteral Feeding Intolerance

Dec 20, 2017: Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency

Nov 27, 2017: Aeterna Zentaris Marketing Authorization Application for Macrilen (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines Agency

Sep 15, 2017: Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)

Sep 06, 2017: Oxeia Biopharmaceuticals Announces Appointment Of Dr. Michael Wyand As Chief Executive Officer

Aug 23, 2017: Richard Sherman, NFL All-Pro, Joins Oxeia Biopharmaceuticals Advisory Board

Jul 18, 2017: NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date

Jun 30, 2017: Aeterna Zentaris Resubmits NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults

Jun 19, 2017: Ammonett Pharma Granted Orphan Drug Designation From the U.S. FDA for Ibutamoren Mesylate (MK-0677) for Treatment of Growth Hormone Deficiency

May 25, 2017: Ammonett Pharma Receives Notice of Allowance of U.S. Patent for Oratrope Related to Detecting and Treating Growth Hormone Deficiency

May 23, 2017: Ammonett Pharma Receives Positive Opinion from European Orphan Medicinal Products Committee for MK-0677 for Treatment of Pediatric Growth Hormone Deficiency

May 18, 2017: Helsinn Announces Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)

May 01, 2017: Allergan to Present Data on Relamorelin at Digestive Disease Week 20

Mar 30, 2017: Aeterna Zentaris Intends to File NDA with Respect to Macrilen in Third Quarter of 20

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Aeterna Zentaris Inc, H1 2018

Pipeline by Allergan Plc, H1 2018

Pipeline by AstraZeneca Plc, H1 2018

Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Pipeline by Millendo Therapeutics Inc, H1 2018

Pipeline by Oxeia Biopharmaceuticals Inc, H1 2018

Pipeline by Pfizer Inc, H1 2018

Pipeline by RaQualia Pharma Inc, H1 2018

Pipeline by Zeria Pharmaceutical Co Ltd, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

Discontinued Products, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Aeterna Zentaris Inc

Allergan Plc

AstraZeneca Plc

Daiichi Sankyo Co Ltd

Millendo Therapeutics Inc

Oxeia Biopharmaceuticals Inc

Pfizer Inc

RaQualia Pharma Inc

Zeria Pharmaceutical Co Ltd

select a license
Single User License
USD 3500 INR 242235
Site License
USD 7000 INR 484470
Corporate User License
USD 10500 INR 726705

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com